Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
  2. Articles
  3. agent for prostate cancer
Show results for
Products
Companies
News
Articles
Refine by
Date

Agent For Prostate Cancer Articles & Analysis

1 articles found
FDA Approved Peptide Drugs in the First Half of 2023

FDA Approved Peptide Drugs in the First Half of 2023

Posluma (flotufolastat F 18) Posluma (flotufolastat F 18) is an 18F-labeled ligand and an imaging agent for the detection and localization of prostate cancer in PET (positron emission tomography). ...

ByCreative Peptides

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you